Concepedia

Ravi Ramjeesingh

RR

16

Publications

804

Citations

15

H-Index

1999

Active since

Affiliations

Dalhousie University(Current)

Queen's University

Princess Margaret Cancer Centre

University of Toronto

Nova Scotia Cancer Centre

Ravi Ramjeesingh is an author at Dalhousie University specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

1999–2024

16

Publications

16

Involvement of Integrin α<sub>v</sub>β<sub>3</sub>and Cell Adhesion Molecule L1 in Transendothelial Migration of Melanoma Cells

Evelyn B. Voura, Ravi Ramjeesingh, Anthony M.P. Montgomery et al. · Molecular Biology of the Cell · 2001 · 197 citations

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox et al. · Nature Communications · 2022 · 119 citations · Full text

The Apical Na+/H+ Exchanger Isoform NHE3 Is Regulated by the Actin Cytoskeleton

Kazuyoshi Kurashima, Sudhir J.A. D’Souza, Katalin Szászi et al. · Journal of Biological Chemistry · 1999 · 116 citations · Full text

Interleukin‐8 secreted by endothelial cells induces Chemotaxis of melanoma cells through the chemokine receptor CXCR1

Ravi Ramjeesingh, Randy Leung, Chi‐Hung Siu · The FASEB Journal · 2003 · 78 citations

, , +14

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

D. J. Renouf, Jennifer J. Knox, Petr Kavan et al. · Annals of Oncology · 2020 · 40 citations

, , +7

Rows per page

1–5 of 16